Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
Recap by typeshit. Full story at Bioengineer.org.
Researchers used AI to identify fungal peptides that taste salty or boost saltiness, aimed at cutting sodium in food. A food science find rather than a drug story.
The 1,200-person trial starts next year with MIT and Pitt researchers, funded by a $13 million Arnold Ventures grant, and will also track housing and jobs.
Researchers found the peptide they built as a treatment already circulates in human blood, at lower levels in people with cognitive impairment.
Lilly Medical points to newly published results from a double-blind, placebo-controlled phase 3 study of its triple-hormone shot in people with diabetes.
A general explainer on how GLP-1 receptor agonists affect blood sugar and appetite, with advice on support while taking them.
Alicia Butterfield claims Anthem denied her Zepbound once the drug got her below morbid obesity. A Los Angeles judge stayed her case pending arbitration.
Loading…